Vitamin D and Cardiovascular Disease.

Vitamin D is best known for its influence on skeletal health. There is growing recognition, however, that vitamin D has nonskeletal actions, which could have important implications for understanding the consequences of vitamin D deficiency. In epidemiologic studies, vitamin D deficiency has been consistently associated with an increased risk for cardiovascular disease and hypertension. Disruption of vitamin D signaling in animal models promotes hypertension, cardiac hypertrophy, and atherosclerosis. This evidence has led to the initiation of prospective randomized trials of vitamin D supplementation in individuals at risk for cardiovascular disease. The results of these trials should help to guide strategies for screening and management of vitamin D deficiency in the clinic and at the population level.

[1]  R. Jorde,et al.  Effect of Vitamin D Supplementation on Blood Pressure: A Systematic Review and Meta-analysis Incorporating Individual Patient Data. , 2015, JAMA internal medicine.

[2]  J. Pankow,et al.  Race and Vitamin D Binding Protein Gene Polymorphisms Modify the Association of 25-Hydroxyvitamin D and Incident Heart Failure: The ARIC (Atherosclerosis Risk in Communities) Study. , 2015, JACC. Heart failure.

[3]  R. Mensink,et al.  Effects of Supplementation with the Fat-Soluble Vitamins E and D on Fasting Flow-Mediated Vasodilation in Adults: A Meta-Analysis of Randomized Controlled Trials , 2015, Nutrients.

[4]  F. Harrell,et al.  Vitamin D Therapy in Individuals With Prehypertension or Hypertension: The DAYLIGHT Trial , 2015, Circulation.

[5]  Ross M. Fraser,et al.  Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study , 2014, The lancet. Diabetes & endocrinology.

[6]  J. Ioannidis,et al.  Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials , 2014, BMJ : British Medical Journal.

[7]  H. DeLuca History of the discovery of vitamin D and its active metabolites. , 2014, BoneKEy reports.

[8]  Ishir Bhan,et al.  Vitamin D-binding protein and vitamin D status of black Americans and white Americans. , 2013, The New England journal of medicine.

[9]  P. Donnan,et al.  Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. , 2013, JAMA internal medicine.

[10]  S. Kunutsor,et al.  Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants , 2013, European Journal of Epidemiology.

[11]  B. Cheung,et al.  Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes. , 2013, Atherosclerosis.

[12]  J. Manson,et al.  Circulating 25-Hydroxy-Vitamin D and Risk of Cardiovascular Disease: A Meta-Analysis of Prospective Studies , 2012, Circulation. Cardiovascular quality and outcomes.

[13]  Christine L. Taylor,et al.  IOM committee members respond to Endocrine Society vitamin D guideline. , 2012, The Journal of clinical endocrinology and metabolism.

[14]  J. Manson,et al.  The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. , 2012, Contemporary clinical trials.

[15]  Christopher S. Law,et al.  Cardiomyocyte-Specific Deletion of the Vitamin D Receptor Gene Results in Cardiac Hypertrophy , 2011, Circulation.

[16]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[17]  S. Larsson,et al.  Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis , 2011, Journal of hypertension.

[18]  B. Horne,et al.  Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. , 2010, The American journal of cardiology.

[19]  Daniel L. Koller,et al.  Common genetic determinants of vitamin D insufficiency: a genome-wide association study , 2010, The Lancet.

[20]  A. Morris,et al.  The effect of different doses of vitamin D3 on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial , 2010, Diabetologia.

[21]  Markku Heliövaara,et al.  Vitamin D status and the risk of cardiovascular disease death. , 2009, American journal of epidemiology.

[22]  K. Schechtman,et al.  1,25(OH)2 Vitamin D Inhibits Foam Cell Formation and Suppresses Macrophage Cholesterol Uptake in Patients With Type 2 Diabetes Mellitus , 2009, Circulation.

[23]  Carlos A Camargo,et al.  Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. , 2009, Archives of internal medicine.

[24]  Christopher S. Law,et al.  Expression of the Vitamin D Receptor Is Increased in the Hypertrophic Heart , 2008, Hypertension.

[25]  W. März,et al.  Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. , 2008, The Journal of clinical endocrinology and metabolism.

[26]  K. Cao,et al.  Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. , 2008, Kidney international.

[27]  E. Rimm,et al.  25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. , 2008, Archives of internal medicine.

[28]  J. Sugden,et al.  Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[29]  D. Tishkoff,et al.  Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. , 2008, Endocrinology.

[30]  Michael J. Pencina,et al.  Vitamin D Deficiency and Risk of Cardiovascular Disease , 2008, Circulation.

[31]  C. Mathieu,et al.  Vitamin D and human health: lessons from vitamin D receptor null mice. , 2008, Endocrine reviews.

[32]  K. Zhu,et al.  Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. , 2008, Archives of internal medicine.

[33]  N. Bodyak,et al.  Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals , 2007, Proceedings of the National Academy of Sciences.

[34]  C. Mathieu,et al.  Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. , 2007, Diabetes research and clinical practice.

[35]  Edward Giovannucci,et al.  Plasma 25-Hydroxyvitamin D Levels and Risk of Incident Hypertension , 2007, Hypertension.

[36]  D. Tishkoff,et al.  1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[37]  R. Simpson,et al.  Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[38]  J. Manson,et al.  Calcium/Vitamin D Supplementation and Cardiovascular Events , 2007, Circulation.

[39]  R. Blumenthal,et al.  Vitamin D supplementation and cardiovascular disease risk. , 2007, Circulation.

[40]  R. Simpson,et al.  Calcitriol modulation of cardiac contractile performance via protein kinase C. , 2006, Journal of molecular and cellular cardiology.

[41]  Xiaoan Ruan,et al.  Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. , 2006, Atherosclerosis.

[42]  M. Aldea,et al.  1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. , 2006, Kidney international.

[43]  G. Targher,et al.  Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. , 2006, Diabetes care.

[44]  E. Warburton,et al.  Reduced Vitamin D in Acute Stroke , 2006, Stroke.

[45]  M. Mathieu,et al.  Clinical and laboratory safety of one year's use of acombination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: Results of a mlticenter, rndomized, double-blind, placebo-controlled study , 2005 .

[46]  N. Stern,et al.  25-Hydroxyvitamin D3-1α-Hydroxylase Is Expressed in Human Vascular Smooth Muscle Cells and Is Upregulated by Parathyroid Hormone and Estrogenic Compounds , 2005, Circulation.

[47]  Yoko Yamamoto,et al.  Disruption of Nuclear Vitamin D Receptor Gene Causes Enhanced Thrombogenicity in Mice* , 2004, Journal of Biological Chemistry.

[48]  Jeffrey B. Cheng,et al.  Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Guilin Qiao,et al.  Vitamin D: a negative endocrine regulator of the renin–angiotensin system and blood pressure , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[50]  R. Doll,et al.  Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial , 2003, BMJ : British Medical Journal.

[51]  T. Shinki,et al.  Characterization of transgenic rats constitutively expressing vitamin D-24-hydroxylase gene. , 2002, Biochemical and biophysical research communications.

[52]  Shu Q. Liu,et al.  1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system , 2002 .

[53]  R. Perez-Fernandez,et al.  Ontogenesis of the vitamin D receptor in rat heart , 2002, Histochemistry and Cell Biology.

[54]  B. Dawson-Hughes,et al.  Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. , 2002, Bone.

[55]  D. Wheeler,et al.  Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. , 2002, Journal of the American Society of Nephrology : JASN.

[56]  S. Cummings,et al.  A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. , 2001, The Journal of clinical endocrinology and metabolism.

[57]  N. Bundred,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Angiogenesis In Vitro and In Vivo , 2000 .

[58]  S. Rostand Ultraviolet light may contribute to geographic and racial blood pressure differences. , 1997, Hypertension.

[59]  A. K. Jarvis,et al.  1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. , 1997, The American journal of physiology.

[60]  T. O’Connell,et al.  IMMUNOCHEMICAL IDENTIFICATION OF THE 1,25‐DIHYDROXYVITAMIN D3RECEPTOR PROTEIN IN HUMAN HEART , 1996, Cell biology international.

[61]  D S Grimes,et al.  Sunlight, cholesterol and coronary heart disease. , 1996, QJM : monthly journal of the Association of Physicians.

[62]  J. Wu,et al.  1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. , 1996, The Journal of clinical investigation.

[63]  A. Dobson,et al.  Seasons, temperature and coronary disease. , 1993, International journal of epidemiology.

[64]  T. Onaya,et al.  Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells. , 1991, Prostaglandins.

[65]  T M Allan,et al.  Composition of Seasonality of Disease , 1991, Scottish medical journal.

[66]  R. Morris,et al.  1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. , 1991, The Journal of clinical investigation.

[67]  R. Beaglehole,et al.  Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. , 1990, International journal of epidemiology.

[68]  D. Saunders,et al.  Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. , 1990, The American journal of physiology.

[69]  A. Fleck LATITUDE AND ISCHAEMIC HEART DISEASE , 1989, The Lancet.

[70]  R. Simpson,et al.  Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. , 1987, The American journal of physiology.

[71]  M. Fanger,et al.  Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. , 1987, The Journal of clinical investigation.

[72]  R. Simpson,et al.  Vitamin D3 and cardiovascular function in rats. , 1987, The Journal of clinical investigation.

[73]  W. Claycomb,et al.  1,25-Dihydroxyvitamin D3 stimulates 45Ca2+ uptake by cultured adult rat ventricular cardiac muscle cells. , 1987, The Journal of biological chemistry.

[74]  M. Walters,et al.  1,25-Dihydroxyvitamin D3 receptors identified in the rat heart. , 1986, Journal of molecular and cellular cardiology.

[75]  R. Simpson,et al.  Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. , 1985, The Journal of biological chemistry.

[76]  A. Voors,et al.  Altitude and arteriosclerotic heart disease mortality in white residents of 99 of the 100 largest cities in the United States. , 1979, Journal of chronic diseases.

[77]  B. Macmahon,et al.  Reduction in mortality from coronary heart disease in men residing at high altitude. , 1977, The New England journal of medicine.